Obiettivo
Patient/individual specific cells, including induced pluripotent stem (iPS) cells will be crucial in defining tomorrow’s medicine owing to their uses in drug discovery, immunotherapy or cell therapy. These clinical applications require the utmost accurate and reliable identity and purity testing, however, the majority of cells stored worldwide fall short of a sufficient level of characterisation. This project aims at validatating and commercializing an innovative method of diagnostic and quality control for human cells. It is based on our unprecedented ability to measure the expression of millions of uncharted RNA biomarkers called TEs, genetic units that contribute over 50% of the genome but that have been completely disregarded until very recently, mainly due to the challenge imposed by their complex analysis. Our new methodology provides a high-density barcode of cellular identity, opening the door for individual-specific cells to broad applications in biotechnology and medicine alike.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesbiological sciencesgeneticsRNA
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesmedical biotechnologycells technologies
Programma(i)
Argomento(i)
Meccanismo di finanziamento
ERC-POC - Proof of Concept GrantIstituzione ospitante
1015 Lausanne
Svizzera